234 related articles for article (PubMed ID: 34445807)
21. Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma.
van Wezel EM; Zwijnenburg D; Zappeij-Kannegieter L; Bus E; van Noesel MM; Molenaar JJ; Versteeg R; Fiocco M; Caron HN; van der Schoot CE; Koster J; Tytgat GA
J Mol Diagn; 2015 Jan; 17(1):43-52. PubMed ID: 25445214
[TBL] [Abstract][Full Text] [Related]
22. Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2.
van den Bijgaart RJE; Kroesen M; Wassink M; Brok IC; Kers-Rebel ED; Boon L; Heise T; van Scherpenzeel M; Lefeber DJ; Boltje TJ; den Brok MH; Hoogerbrugge PM; Büll C; Adema GJ
J Biol Chem; 2019 Mar; 294(12):4437-4449. PubMed ID: 30670592
[TBL] [Abstract][Full Text] [Related]
23. Gangliosides and Neuroblastomas.
Schengrund CL
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32726962
[TBL] [Abstract][Full Text] [Related]
24. Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.
Stutterheim J; Zappeij-Kannegieter L; Ora I; van Sluis PG; Bras J; den Ouden E; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Mol Diagn; 2012; 14(2):168-75. PubMed ID: 22251610
[TBL] [Abstract][Full Text] [Related]
25. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
26. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
[TBL] [Abstract][Full Text] [Related]
27. Neuroblastoma cells can be classified according to glycosphingolipid expression profiles identified by liquid chromatography-tandem mass spectrometry.
Kaneko T; Okita H; Nakajima H; Iijima K; Ogasawara N; Miyagawa Y; Katagiri YU; Nakagawa A; Kiyokawa N; Sato T; Fujimoto J
Int J Oncol; 2010 Nov; 37(5):1279-88. PubMed ID: 20878075
[TBL] [Abstract][Full Text] [Related]
28. Higher levels of minimal residual disease in peripheral blood than bone marrow before 1st and 2nd relapse/regrowth in a patient with high‑risk neuroblastoma: A case report.
Inoue S; Win KHN; Mon CY; Fujikawa T; Hyodo S; Uemura S; Ishida T; Mori T; Hasegawa D; Kosaka Y; Nishimura A; Nakatani N; Nino N; Tamura A; Yamamoto N; Nozu K; Nishimura N
Oncol Lett; 2023 Sep; 26(3):369. PubMed ID: 37559575
[TBL] [Abstract][Full Text] [Related]
29. Low complex ganglioside expression characterizes human neuroblastoma cell lines.
Hettmer S; Ladisch S; Kaucic K
Cancer Lett; 2005 Jul; 225(1):141-9. PubMed ID: 15922866
[TBL] [Abstract][Full Text] [Related]
30. State of the art in immunotherapy of neuroblastoma.
Jabbari P; Hanaei S; Rezaei N
Immunotherapy; 2019 Jun; 11(9):831-850. PubMed ID: 31094257
[TBL] [Abstract][Full Text] [Related]
31. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse.
Raffaghello L; Marimpietri D; Pagnan G; Pastorino F; Cosimo E; Brignole C; Ponzoni M; Montaldo PG
Cancer Lett; 2003 Jul; 197(1-2):205-9. PubMed ID: 12880983
[TBL] [Abstract][Full Text] [Related]
32. Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy.
Gorostegui M; Muñoz JP; Perez-Jaume S; Simao-Rafael M; Larrosa C; Garraus M; Salvador N; Lavarino C; Krauel L; Mañe S; Castañeda A; Mora J
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730688
[TBL] [Abstract][Full Text] [Related]
33. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.
Cheung IY; Lo Piccolo MS; Kushner BH; Kramer K; Cheung NK
J Clin Oncol; 2003 Mar; 21(6):1087-93. PubMed ID: 12637475
[TBL] [Abstract][Full Text] [Related]
34. Cytotoxicity of L-cycloserine against human neuroblastoma and medulloblastoma cells is associated with the suppression of ganglioside expression.
Cinatl J; Cinatl J; Kotchetkov R; Pouckova P; Vogel JU; Rabenau H; Michaelis M; Kornhuber B
Anticancer Res; 1999; 19(6B):5349-54. PubMed ID: 10697560
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy of Neuroblastoma: Facts and Hopes.
Anderson J; Majzner RG; Sondel PM
Clin Cancer Res; 2022 Aug; 28(15):3196-3206. PubMed ID: 35435953
[TBL] [Abstract][Full Text] [Related]
36. A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics.
Zhang L; Wang M; Zhu Z; Chen S; Wu H; Yang Y; Che F; Li Q; Li H
Mol Ther Nucleic Acids; 2021 Dec; 26():732-748. PubMed ID: 34703655
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma.
Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Montaldo PG; Gambini C; Allen TM; Bogenmann E; Ponzoni M
Int J Cancer; 2003 May; 104(5):559-67. PubMed ID: 12594810
[TBL] [Abstract][Full Text] [Related]
38. Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.
Müller J; Reichel R; Vogt S; Müller SP; Sauerwein W; Brandau W; Eggert A; Schramm A
PLoS One; 2016; 11(10):e0163648. PubMed ID: 27716771
[TBL] [Abstract][Full Text] [Related]
39. The ganglioside G
Balis FM; Busch CM; Desai AV; Hibbitts E; Naranjo A; Bagatell R; Irwin M; Fox E
Pediatr Blood Cancer; 2020 Jan; 67(1):e28031. PubMed ID: 31612589
[TBL] [Abstract][Full Text] [Related]
40. New method for quantitative analysis of GD2 ganglioside in plasma of neuroblastoma patients.
Czaplicki D; Horwacik I; Kowalczyk A; Wieczorek A; Bolek-Marzec K; Balwierz W; Kozik A; Rokita H
Acta Biochim Pol; 2009; 56(3):423-31. PubMed ID: 19724779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
